The National Research Council of Canada (NRC) is seeking a co-founder to jointly establish, with the NRC, a not-for-profit corporation to govern the Biologics Manufacturing Centre.

Under the governance of this new not-for-profit corporation, the Biologics Manufacturing Center will have the agility to operate with the efficiency of the private sector, while focusing on fulfilling a public good mandate which includes maximizing pandemic preparedness and response, supporting public- good projects, and contributing to the growth and resilience of Canada’s life sciences sector.

With relevant not-for-profit and biomanufacturing operational experience, the co-founder will be fully involved in setting up the not-for-profit corporation and in the transition of the Biologics Manufacturing Centre’s operations, including the existing, highly skilled operations team.

In the longer term, the co-founder will work jointly with the not-for-profit’s board of directors to advance the strategic plan for the Biologics Manufacturing Centre, in alignment with its mandate as a key element in the Government of Canada’s broader Biomanufacturing and Life Sciences Strategy.

Operating a brand new end-to-end biomanufacturing facility to fulfill a public-good mandate is an exciting opportunity for an organization with the right experience and entrepreneurial drive. This is an opportunity to provide strategic leadership and vision for the Biologics Manufacturing Centre, and shape the future of this important asset for Canada.

The National Research Council of Canada (NRC) is looking for a co-founder to jointly establish a not-for-profit company (EBNL) that will govern the Biologics Production Center (CPPB).

Under the governance of this new venture, the CPPB will have the flexibility to operate with the efficiency of the private sector, while focusing on achieving a public interest mandate, maximizing pandemic preparedness and response, by supporting projects of public interest and contributing to the growth and resilience of the life sciences sector in Canada.

With relevant operational experience in the field of biologics and non-profit manufacturing, the co-founder will fully participate in the establishment of EBNL and the transition of CPPB’s activities, including the team existing operational, highly qualified.

In the longer term, the co-founder will work jointly with the EBNL Board of Directors to pursue the strategic plan of the CPPB, in line with its mandate as a key element of the Biomanufacturing and Life Sciences Strategy. of the Government of Canada.

Operating a brand new end-to-end biomanufacturing facility to fulfill a public interest mandate is a great opportunity for an organization that has the necessary experience and entrepreneurial spirit. This is an opportunity to provide strategic leadership and vision for CPPB, and to shape the future of this important Canadian asset.

Essential Qualifications

Organizations (companies, associations, academic institutions) wishing to apply must be operating in Canada in the biomanufacturing or life sciences sector at the time of business case submission and be able to demonstrate the experience and expertise required to contribute to the strategic direction and long-term success of EBNL, covering areas such as:

• operation and maintenance of facilities certified in accordance with good manufacturing practices;
• operation of a complete (i.e., end-to-end) biomanufacturing facility, in particular for the manufacture of cell-based biopharmaceuticals;
• establishment and supervision of the operations of an EBNL;
• strategies to fulfill a public good mandate and ensure the financial viability of operations.

Next Steps

If your organization wishes to apply to create an EBNL with the NRC to govern the CPPB:

• go to the CPPB’s call for a co-founder page for more information;
• Email us at NRC.BioManufacturingCentre-CentreProductionProduitsBio.CNRC@nrc-cnrc.gc.ca for the business case submission guide.

Date to remember

Launch of the call for a co-founder of the CPPB: June 27, 2022
Virtual information session: July 6, 2022
End of the call: August 1 , ²⁰²²

Original source here.